THOMAS SCIASCIA
CIK 1229946 · Chief Scientific Officer · last filed 2026-02-20
THOMAS SCIASCIA is a Chief Scientific Officer who has filed 26 SEC Form 4 insider transactions across 2 companies since 2007. The most recent filing, for TRVI, was dated Feb 20, 2026. Across all open-market trades the lifetime net is −$289.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.15M
2
26
-$289.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVI | Chief Scientific Officer | 221,373 | $14.21 | $3.15M | -$289.6K | 18 | 2026-02-20 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | SVP Clin Dev & Reg Aff & CMO | 0 | — | — | $0 | 8 | 2010-09-22 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-20 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2025-06-03 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2025-03-26 | TRVI | Mixed | — | -$13.6K | EDGAR |
| 2025-03-12 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2025-02-20 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2024-08-21 | TRVI | Mixed | — | -$25.3K | EDGAR |
| 2024-08-16 | TRVI | Mixed | — | -$42.2K | EDGAR |
| 2024-05-31 | TRVI | Mixed | +5,986 | -$6.1K | EDGAR |
| 2024-02-16 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2023-02-16 | TRVI | Grant (A) | — | $0 | EDGAR |